Loading
companiesCompany
GERCOR
aka GERCOR - Multidisciplinary Oncology Cooperative Group, Groupe Coopérateur Multidisciplinaire en Oncologie
GERCOR is a French non-profit cooperative group created in 1997 that sponsors its own phase 2 and 3 solid tumour trials through a network of about 300 investigators; in OnCo it leads LAP07 in locally advanced pancreatic cancer.
Overview
GERCOR was created in 1997 as a non-profit entity whose mission is to improve treatment for patients with solid tumours through innovative multidisciplinary clinical research; it sponsors phase 2 and phase 3 trials independently and draws on a national network of 300 members in about a hundred centres, from an office at 151 rue du Faubourg Saint-Antoine, Paris (gercor.com). ClinicalTrials.gov registers it as GERCOR - Multidisciplinary Oncology Cooperative Group (OTHER class) and names it lead sponsor of LAP07 (NCT00634725, phase 3, chemoradiotherapy against chemotherapy alone after induction in locally advanced pancreatic cancer), the trial recorded in OnCo. It has no products of its own.
Similar pages
not linked directly; found by shared links- CompanyDutch Pancreatic Cancer Group
Shares Pancreatic ductal adenocarcinoma and the tag cooperative-group.
- TrialFOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
- TrialAcoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
- Key paperLAP07: chemoradiotherapy versus chemotherapy after four months of gemcitabine in locally advanced pancreatic cancer
Shares LAP07, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
- PersonTobias Janowitz
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
- TrialIntra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
- TrialClinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
- TrialSafety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.